Mersana Therapeutics (Mersana Therapeutics) Days Inventory : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Mersana Therapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $0.00 Mil. Mersana Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Mersana Therapeutics's Days Inventory or its related term are showing as below:

MRSN's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 191.36
* Ranked among companies with meaningful Days Inventory only.

Mersana Therapeutics's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Mersana Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.00.

Mersana Therapeutics Days Inventory Historical Data

The historical data trend for Mersana Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Days Inventory Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mersana Therapeutics's Days Inventory

For the Biotechnology subindustry, Mersana Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Days Inventory falls into.

Mersana Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Mersana Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Mersana Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Mersana Therapeutics (NAS:MRSN) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Mersana Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mersana Therapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	10.701
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Mersana Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (Mersana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Executives

Anna Protopapas	director, officer: President and CEO	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala	officer: SVP, Chief Development Officer	C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra	officer: Chief Manufacturing Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner	officer: Sr. VP, Finance & Product stgy	840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia	officer: VP, Controller	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger	officer: Chief Scientific Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang	officer: Chief Medical Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman	officer: Sr VP Chmistry, Man & Control	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack	officer: CBO, Treasurer & Secretary	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell	10 percent owner